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Objectives. We sought to evaluate the relation between warfarin
anticoagulation and survival and morbidity from cardiac disease
in patients with left ventricular (LV) dysfunction.
Background. Warfarin anticoagulation plays a major role in the
management of patients who have had a large myocardial infarc-
tion and in those with atrial fibrillation. However, its use in
patients with LV systolic dysfunction has been controversial.
Methods. We reviewed data on warfarin use in 6,797 patients
enrolled in the Studies of Left Ventricular Dysfunction (SOLVD)
trial and analyzed the relation between warfarin use and all-cause
mortality, as well as the combined end point of death or hospital
admission for heart failure. We used Cox regression to adjust for
differences in baseline characteristics and to test for the interac-
tion between warfarin use and selected patient variables in
relation to outcome.
Results. On multivariate analysis, use of warfarin was associ-
ated with a significant reduction in all-cause mortality (adjusted
hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.65 to 0.89,
p 5 0.0006) and in the risk of death or hospital admission for
heart failure (HR 0.82, 95% CI 0.72 to 0.93, p 5 0.0002). Risk
reduction was observed when each trial or randomization arm was
analyzed separately, as well as in both genders. It was not
significantly influenced by the presence of atrial fibrillation, age,
ejection fraction, New York Heart Association functional class or
etiology.
Conclusions. In patients with LV systolic dysfunction, warfarin
use is associated with improved survival and reduced morbidity.
This association is primarily due to a reduction in cardiac events
and does not appear to be limited to any particular subgroup.
(J Am Coll Cardiol 1998;31:749–53)
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The use of warfarin in patients with heart failure (HF) has
been the subject of considerable controversy. Patients with
severe left ventricular (LV) systolic dysfunction are thought to
be at greater risk of developing arterial and venous thrombo-
embolic complications. The increase in risk in this group of
patients is multifactorial and is probably related to a combina-
tion of low cardiac output, aberrant blood flow dynamics and
stasis, abnormal endocardial surface, left atrial enlargement
and atrial fibrillation. Venous stasis may also occur and, when
coupled with reduced activity, can contribute to the risk of
venous thromboembolism. Recent evidence also suggests that
patients with LV systolic dysfunction may be in a chronic
hypercoagulable state (1–3). Several population-based cohort
studies have sought to quantitate the risk of arterial and
venous thrombosis and embolism. Estimates of such risks
varied among the different studies, but in general they were
surprisingly low (4–6).
Despite these findings, several experts have recommended
the use of anticoagulant agents in patients with HF (7,8) to
reduce thromboembolic events. In addition, warfarin use in
patients with coronary artery disease, especially after a large
myocardial infarction (MI), reduces the likelihood of nonfatal
MI (9–12), and therefore may retard the progression of HF. In
patients recovering from MI, warfarin therapy also reduces the
risk of thromboembolic strokes (9).
The purpose of our analysis was to evaluate the relation
between warfarin use and survival and cardiovascular morbid-
ity in patients with LV systolic dysfunction enrolled in the
Studies of Left Ventricular Dysfunction (SOLVD) trial.
Methods
Patients. The Studies of Left Ventricular Dysfunction trial
was a multicenter, randomized, double-blind, placebo-
controlled investigation that examined the effect of enalapril
on morbidity and mortality in patients with LV systolic dys-
function, defined as an ejection fraction (EF) #0.35 (13,14).
Patients receiving treatment other than angiotensin-converting
enzyme inhibitors for symptoms of HF were enrolled in the
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treatment trial; patients without such symptoms were enrolled
in the prevention trial. Patients were ineligible if they were
.80 years of age or had any of the following: hemodynamically
serious valvular heart disease requiring surgical treatment,
unstable angina pectoris, angina thought to be severe enough
to require revascularization procedures, MI during the previ-
ous month, severe pulmonary disease, serum creatinine level
.177 mmol/liter (2 mg/dl) or any other disease that might
substantially shorten survival or impede participation in a
long-term trial. In total, 6,797 patients were enrolled in both
trials. Ventricular function was assessed by contrast angiogra-
phy, radionuclide ventriculography or two-dimensional echo-
cardiography. The baseline study visit included a comprehen-
sive review of the patients’ medical history, and patients were
specifically asked whether they were taking certain medications
regularly, including warfarin and those drugs listed in Table 1.
After randomization to enalapril or placebo, patients were
regularly evaluated, and their clinical status, including the
development of HF, hospital admissions, adherence to study
regimen and adverse effects, was recorded at each follow-up
visit. For patients who died or were admitted to the hospital,
the cause of death or the primary reason for hospital admission
was evaluated and classified by an investigator who had no
knowledge of the study treatment.
We reviewed data on the use of warfarin anticoagulation
collected on the baseline data form. All patients in both trials
with complete data were included in the analysis. The end
points of all-cause mortality, death or hospital admission for
HF, cardiovascular deaths, sudden death without antecedent
worsening HF, death due to HF, fatal MI and noncardiac
vascular causes of death were evaluated and correlated with
warfarin use.
Statistical analysis. The primary outcome measures were
occurrence of death and length of survival (time from entry
into the study to either death, end of study or loss to
follow-up). In addition, hospital admission for unstable angina
and nonfatal MI were evaluated. Risk factors of primary
interest were use of anticoagulant agents, randomization to
enalapril and trial (treatment or prevention). The chi-square
test for independence was used to analyze unadjusted mortal-
ity rates and to calculate relative risk (RR) and 95% confi-
dence intervals (CI). Kaplan-Meier survival analysis was used
to examine duration of survival, with log-rank tests to compare
survival analysis curves between subsets of patients.
Cox regression was used to adjust for potential influence of
confounding factors on survival. These include age, gender,
etiology, trial assignment, study drug randomization, EF, New
York Heart Association functional class, history of atrial
fibrillation, history of cerebrovascular disease and baseline
drug therapy with antiplatelet agents, antiarrhythmic drugs or
digitalis. Results are reported as the adjusted hazard ratio
(HR) with 95% CIs and p values. Throughout, p , 0.05 was
considered statistically significant. The computer statistical
software package SPSS, version 7.5, was used for all analyses.
Based on the total number of patients analyzed and the
ratio of warfarin users to nonusers (1:6.5), and assuming an
end point incidence of 25% in the nonusers group, our analysis
had 90% power to detect an RR reduction of 20%, with 95%
confidence.
Results
Patients. Of 6,797 patients enrolled (2,569 in the treatment
trial and 4,228 in the prevention trial), 6,513 were considered
in the final analysis. Two hundred eighty-four patients (4.2%)
were excluded because of missing baseline data. Mean
Abbreviations and Acronyms
CI 5 confidence interval
EF 5 ejection fraction
HF 5 heart failure
HR 5 hazard ratio
LV 5 left ventricular
MI 5 myocardial infarction
RR 5 relative risk
SOLVD 5 Studies of Left Ventricular Dysfunction
Table 1. Baseline Clinical Characteristics and Drug Therapy of







(n 5 5,652) p Value
Randomization group
(% randomized to enalapril)
48.6 50.2 0.4
Age (years) 58.5 6 10.8 59.7 6 10.1 , 0.0001
Men 87.0 85.4 0.2
EF (%) 26.2 6 6.6 27.1 6 6.2 , 0.0001





History of 28.9 36.3 0.0002
Atrial fibrillation 19.3 4.5 , 0.0001
Cerebrovascular disease 13.8 5.5 , 0.0001
Diabetes mellitus 14.6 20.0 0.0001
Hypertension 34.4 39.8 0.002
Smoking 78.2 78.3 0.9
Etiology
Ischemic 67.6 80.6 , 0.0001
Nonischemic 32.4 19.4 , 0.0001
Baseline drug therapy
Antiarrhythmic agents 24 16.7 , 0.0001
Antiplatelet agents 17.7 50.9 , 0.0001
Beta-blockers 13.3 18.6 , 0.0001
Digitalis 50.3 30.5 , 0.0001
Diuretic agents 48.8 41.8 ,0.0001
Nitrates 32 35.1 0.07
*Two hundred eighty-four patients had missing baseline data. Data are
presented as mean value 6 SD or percentage of patients. EF 5 ejection fraction;
NYHA 5 New York Heart Association.
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follow-up was 41.4 months in the treatment trial and 37.4
months in the prevention trial. The clinical characteristics of
warfarin users and nonusers in the combined trial are shown in
Table 1. Of the total group, 861 patients (13.2%) reported
baseline warfarin use, whereas the remainder did not. Patients
using warfarin were slightly younger and less frequently com-
plained of angina. They also had a lower mean EF, worse
functional class, more frequent atrial fibrillation, cerebrovas-
cular disease and more frequent use of antiarrhythmic agents
and digitalis. They were less likely to have an ischemic etiology
and less likely to use antiplatelet agents or beta-blockers. The
proportion of men and frequency of randomization to enala-
pril were not different between the two groups. These differ-
ences were consistent when the treatment and prevention trials
were analyzed separately.
All-cause mortality and causes of death. There were 210
deaths among the patients who reported warfarin use, com-
pared with 1,334 deaths among the patients who did not use
warfarin (RR 1.03, 95% CI 0.91 to 1.17) (Table 2). Of those
deaths, 177 in the warfarin use group and 1,181 in the nonuse
group were due to cardiovascular disease (RR 0.99, 95% CI
0.86 to 1.14) (Table 3).
After adjusting for baseline differences, warfarin use was a
highly significant predictor of favorable outcome (Table 2 and
3). In the combined group, warfarin use was associated with an
HR of 0.76 for all-cause mortality (95% CI 0.65 to 0.89, p 5
0.0006) (Fig. 1). Mortality due to cardiovascular disease was
also significantly reduced (HR 0.72, 95% CI 0.61 to 0.86, p 5
0.0002) (Table 3). Hazard reduction was consistent among the
various causes of cardiac death, although the reduction in fatal
MI appeared to be more pronounced. There was no reduction
in fatal noncardiac vascular events, including deaths due to
stroke, pulmonary embolism or other vascular causes.
Death or hospital admission for HF. Among the patients
who reported warfarin use, there were 306 deaths or hospital
admissions for HF, compared with 1,910 deaths among those
who did not use warfarin (RR 1.05, 95% CI 0.95 to 1.16)
(Table 2). After adjusting for differences in baseline charac-
teristics, warfarin use was associated with a significant reduc-
tion in this end point (HR 0.82, 95% CI 0.72 to 0.93, p 5 0.002)
(Fig. 2 and Table 2). This benefit appeared to be driven
primarily by a reduction in all-cause mortality.
Hospital admission for unstable angina and nonfatal MI.
In the combined group, there were 185 admissions for unstable
angina and 36 admissions for nonfatal MI among patients
receiving warfarin compared with 1,407 admissions for unsta-
ble angina and 409 admissions for nonfatal MI among those
not using warfarin (RR 0.86, 95% CI 0.75 to 0.99, p 5 0.03 for
unstable angina, and RR 0.58, 95% CI 0.41 to 0.81, p 5 0.001
for nonfatal MI) (Table 4).
After adjusting for differences in baseline characteristics,
warfarin use was associated with a 44% reduction in hospital
admission for nonfatal MI (p 5 0.002) and with a nonsignifi-
cant trend toward reducing admissions for unstable angina
(Table 4).
Association between warfarin use and end points in differ-
ent subgroups. The relation between warfarin use and the
various end points was analyzed by age, gender, etiology, EF,
functional class, trial assignment (treatment and prevention),
randomization to enalapril and the presence or absence of
atrial fibrillation. Interaction terms were introduced into the
Cox regression analysis, with adjustment for confounding
Table 2. Unadjusted Risk and Adjusted Hazard Ratios for All-Cause Mortality and Death or Hospital Admission for Heart Failure in
Warfarin Users Versus Nonusers in the Studies of Left Ventricular Dysfunction Combined Trial
End Point W1 (%) W2 (%) RR (95% CI) p Value HR (95% CI) p Value
All-cause mortality 24.4 23.6 1.03 (0.91–1.17) 0.6 0.76 (0.65–0.89) 0.0006
Death or hospital admission for HF 35.5 33.8 1.05 (0.95–1.16) 0.3 0.82 (0.72–0.93) 0.002
CI 5 confidence interval; HF 5 heart failure; HR 5 adjusted hazard ratio; RR 5 relative risk; W1 5 warfarin users; W2 5 warfarin nonusers.
Table 3. Unadjusted Relative Risk and Adjusted Hazard Ratios for Causes of Death in Warfarin Users Versus Nonusers in the Studies of
Left Ventricular Dysfunction Combined Trial
End Point W1 (%) W2 (%) RR (95% CI) p Value HR (95% CI) p Value
Cardiovascular deaths 20.6 20.9 0.99 (0.86–1.14) 0.9 0.72 (0.61–0.86) 0.0002
Sudden death not preceded by HF 5.2 6.3 0.83 (0.61–1.12) 0.2 0.66 (0.47–0.91) 0.01
Death associated with HF 10.9 9.8 1.12 (0.91–1.38) 0.3 0.77 (0.61–0.98) 0.03
Fatal MI 2.3 3.1 0.76 (0.48–1.20) 0.2 0.55 (0.34–0.90) 0.02
Noncardiac vascular deaths 1.6 1.2 1.33 (0.75–2.36) 0.3 0.99 (0.53–1.64) 1.00
Fatal stroke 0.8 0.6 1.28 (0.57–2.86) 0.6 0.80 (0.32–1.97) 0.6
Fatal pulmonary embolism 0.6 0.4 1.64 (0.62–4.37) 0.3 1.65 (0.57–4.78) 0.4
Other vascular deaths 0.2 0.2 1.01 (0.23–4.46) 1.0 0.77 (0.16–3.71) 0.7
MI 5 myocardial infarction; other abbreviations as in Table 2.
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variables. The presence of a significant interaction (p , 0.05)
was considered to indicate dependence of the association
between warfarin use and survival on the presence of or
variation in any of these variables. There was no significant
interaction between warfarin-associated mortality reduction,
reduction in the end point of death or hospital admission for
HF or reduction in hospital admission for nonfatal MI and any
of these variables. The same was also true when both trials
were analyzed separately. Table 5 shows the HR for all-cause
mortality in different subgroups when patients are classified by
trial, randomization arm, etiology and presence or absence of
atrial fibrillation. In all subgroups there is a consistent trend
toward a reduction in this end point. A consistent pattern was
also observed when the end point of death or hospital admis-
sion for HF was analyzed in these subgroups.
Discussion
The use of warfarin in the management of patients with HF
is controversial. Estimates vary regarding the risk of arterial
and venous thromboembolism among these patients. In a
group of patients with dilated cardiomyopathy, Fuster et al. (4)
estimated the incidence of arterial embolism to be 3.5 per 100
patient-years. Later estimates (5,6,8) varied from 1.4 to 42.4
per 100 patient-years, depending on the characteristics of the
group studied (severity of LV dysfunction, LV size and the
presence of atrial fibrillation), method of documenting events
(clinical vs. autopsy) and referral base. For example, the
highest estimate of thromboembolism came from a thrombosis
referral center (8). Reports also differ regarding the degree of
correlation between the severity of LV dysfunction, or other
clinical variables, and the likelihood of arterial or pulmonary
thromboembolism (6,8).
This study is the first to examine the relation between
warfarin use and long-term survival in a large cohort of
patients selected primarily on the basis of LV systolic dysfunc-
tion. Because patients were not randomized to receive warfa-
rin, significant differences in baseline characteristics between
users and nonusers were present. Generally, warfarin users had
less favorable baseline characteristics. We attempted to adjust
for these differences by including relevant characteristics in a
multivariate Cox regression model. The primary results of this
analysis show that baseline warfarin use in patients with an EF
#35% (with and without symptoms of HF) is associated with a
significant reduction in all-cause mortality, in the combined
end point of death or hospital admission for HF and in hospital
admissions for acute coronary syndromes, primarily in the
number of admissions for nonfatal MI. In addition, we found
that this association was consistent in important clinical sub-
groups and that it was not influenced by age, gender, functional
class, EF or presence of atrial fibrillation.
In patients recovering from acute MI, warfarin anticoagu-
lation reduces mortality, fatal and nonfatal coronary events,
pulmonary embolism and stroke, when started within 4 weeks
from the onset of symptoms (9). Other studies in the chronic
phase of coronary disease have suggested a similar reduction in
coronary events, but not in overall mortality. In our analysis,
the reduction in all-cause mortality was mainly driven by a
reduction in cardiac mortality. This reduction, however, could
not be attributed to one specific mode of cardiac death. We
observed a significant reduction in fatal MI and in sudden
death. The reduction in hospital admissions for nonfatal
MI and unstable angina may have contributed to the reduction
in deaths associated with worsening HF. Patients with HF
may manifest a hypercoagulable state, as evidenced by in-
creased plasma and blood viscosity, platelet activation and
increased plasma levels of beta-thromboglobulin, thrombin–
antithrombin complex, fibrinopeptide A, D-dimer and von
Willibrand factor (1–3). There is, however, no consistent
association between the presence of these markers of hyper-
coagulability and either the clinical severity of HF, etiology,
degree of neurohormonal activation or EF, and they do not
clearly predict the likelihood of clinical events (1–3).
Our data did not show a reduction in noncardiac vascular
deaths or hospital admissions for noncardiac vascular events in
association with warfarin use. This negative finding is probably
multifactorial: higher risk patients were more likely to receive
anticoagulation, and in this group, the risk of fatal vascular
events was small (,2%). In addition, unless the diagnosis is
made before death, it is possible that many cases of fatal
pulmonary embolism are labeled as sudden death or acute HF.
Figure 1. Adjusted all-cause mortality in warfarin users (W1) and
nonusers (W2) in the combined SOLVD trial.
Figure 2. Adjusted hazard of death or hospital admission for HF in
warfarin users (W1) and nonusers (W2) in the combined SOLVD
trial.
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The findings from our analysis have significant implications
with regard to the treatment of patients with LV systolic
dysfunction. Benefit associated with warfarin use in this group
of patients is not limited to a reduction in certain vascular
events in high risk subgroups (e.g., those with atrial fibrillation)
and is not limited to patients with symptoms of HF. Unfortu-
nately, because of a lack of data on the intensity of anticoag-
ulation, no recommendations can be made in that regard.
Despite a lack of data from this study on the risks of antico-
agulation, maintaining a therapeutic International Normalized
Ratio in the range of 2 to 3 has been shown in multiple, large,
randomized trials to be associated with ,1.5% risk of major
bleeding (15). It is unlikely that patients with LV dysfunction
should require anticoagulation outside this range or would
have a different complication profile associated with warfarin
use.
Strengths and limitations. Our analysis has important
strengths, including a large sample size, prospective definition
of end points and collection of data, long follow-up time,
availability of data for most patients (.95%) and consistency
of the results in different subgroups. However, it has limita-
tions common to cohort studies, including its retrospective
nature and lack of randomization. Data on the intensity of
anticoagulation and bleeding complications of anticoagulation
were not available, nor were follow-up data available, including
warfarin use throughout the study period.
Conclusions. The use of warfarin anticoagulation in pa-
tients with LV systolic dysfunction is associated with improved
survival and reduced morbidity. This association is not influ-
enced by age, gender, etiology, functional class, presence or
absence of atrial fibrillation, EF or use of enalapril. In the
absence of randomized controlled data, the present findings
support the use of warfarin in patients whose LVEF is #35%,
including those in sinus rhythm.
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Table 4. Hospital Admission for Unstable Angina or Nonfatal Myocardial Infarction in Warfarin Users Versus Nonusers in the Studies of





(%)* RR (95% CI) p Value HR (95% CI) p Value
Hospital admissions for unstable angina 21.5 24.9 0.86 (0.75–0.99) 0.03 0.91 (0.75–1.10) 0.3
Hospital admissions for nonfatal MI 4.2 7.2 0.58 (0.41–0.81) 0.001 0.56 (0.39–0.82) 0.002
Hospital admissions for unstable angina or nonfatal MI 25.7 32.1 0.80 (0.71–0.90) 0.0001 0.79 (0.67–0.95) 0.01
Patients admitted with unstable angina or nonfatal MI 16.5 20.2 0.82 (0.70–0.96) 0.01 0.85 (0.67–1.08) 0.2
*The denominator for percentages is the number of patients in each group. Abbreviations as in Tables 2 and 3.
Table 5. Adjusted Hazard Ratios for All-Cause Mortality in
Warfarin Users Versus Nonusers in Subgroups of the Studies of
Left Ventricular Dysfunction Combined Population
Subgroup
No. of
W1/W2 HR (95% CI) p Value
Treatment trial 396/2,096 0.77 (0.64–0.93) 0.007
Prevention trial 465/3,556 0.73 (0.56–0.96) 0.02
Enalapril arm 425/2,832 0.83 (0.66–1.03) 0.09
Placebo arm 436/2,820 0.70 (0.56–0.87) 0.001
Ischemic etiology 576/4,547 0.83 (0.69–1.00) 0.048
Nonischemic etiology 284/1,101 0.66 (0.50–0.87) 0.004
Atrial fibrillation 166/253 0.66 (0.45–0.97) 0.04
No atrial fibrillation 695/5,399 0.79 (0.66–0.93) 0.006
Abbreviations as in Table 2.
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